Auteurs
Checkpoint
Ncbi
Racine
Checkpoint
Ncbi
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Auteurs » - entrée « Nobuyuki Miyasaka »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Nobuyuki Horita < Nobuyuki Miyasaka < Nobuyuki Nosaka  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000042 (2007) Norihiro Nishimoto [Japon] ; Jun Hashimoto ; Nobuyuki Miyasaka ; Kazuhiko Yamamoto ; Shinichi Kawai ; Tsutomu Takeuchi ; Norikazu Murata ; Désirée Van Der Heijde ; Tadamitsu KishimotoStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
000110 (2009) Norihiro Nishimoto [Japon] ; Nobuyuki Miyasaka ; Kazuhiko Yamamoto ; Shinichi Kawai ; Tsutomu Takeuchi ; Junichi Azuma ; Tadamitsu KishimotoStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
000149 (2009) Jun Hashimoto [Japon] ; Patrick Garnero ; Désirée Van Der Heijde ; Nobuyuki Miyasaka ; Kazuhiko Yamamoto ; Shinichi Kawai ; Tsutomu Takeuchi ; Hideki Yoshikawa ; Norihiro NishimotoA combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
000161 (2009) Ryuji Koike [Japon] ; Masayoshi Harigai ; Tatsuya Atsumi ; Koichi Amano ; Shinichi Kawai ; Kazuyoshi Saito ; Tomoyuki Saito ; Masahiro Yamamura ; Tsukasa Matsubara ; Nobuyuki MiyasakaJapan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.
000254 (2010) Jun Hashimoto [Japon] ; Patrick Garnero [France] ; Désirée Van Der Heijde [Pays-Bas] ; Nobuyuki Miyasaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Shinichi Kawai [Japon] ; Tsutomu Takeuchi [Japon] ; Hideki Yoshikawa [Japon] ; Norihiro Nishimoto [Japon]Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study
000465 (2011) Kayoko Kaneko [Japon] ; Yoshishige Miyabe [Japon] ; Aiko Takayasu [Japon] ; Shin Fukuda [Japon] ; Chie Miyabe [Japon] ; Masashi Ebisawa [Japon] ; Waka Yokoyama [Japon] ; Kaori Watanabe [Japon] ; Toshio Imai [Japon] ; Kenzo Muramoto [Japon] ; Yuya Terashima [Japon] ; Takahiko Sugihara [Japon] ; Kouji Matsushima [Japon] ; Nobuyuki Miyasaka [Japon] ; Toshihiro Nanki [Japon]Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis
000577 (2012) Ryoko Sakai [Japon] ; Michi Tanaka ; Toshihiro Nanki ; Kaori Watanabe ; Hayato Yamazaki ; Ryuji Koike ; Hayato Nagasawa ; Koichi Amano ; Kazuyoshi Saito ; Yoshiya Tanaka ; Satoshi Ito ; Takayuki Sumida ; Atsushi Ihata ; Yoshiaki Ishigatsubo ; Tatsuya Atsumi ; Takao Koike ; Atsuo Nakajima ; Naoto Tamura ; Takao Fujii ; Hiroaki Dobashi ; Shigeto Tohma ; Takahiko Sugihara ; Yukitaka Ueki ; Akira Hashiramoto ; Atsushi Kawakami ; Noboru Hagino ; Nobuyuki Miyasaka ; Masayoshi HarigaiDrug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
000585 (2013) Akito Takamura [Japon] ; Shintaro Hirata ; Hayato Nagasawa ; Hideto Kameda ; Yohei Seto ; Tatsuya Atsumi ; Makoto Dohi ; Takao Koike ; Nobuyuki Miyasaka ; Masayoshi HarigaiA retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.
000733 (2013) Yusuke Matsuo ; Fumitaka Mizoguchi ; Hitoshi Kohsaka ; Eisaku Ito ; Yoshinobu Eishi ; Nobuyuki MiyasakaTocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis.
000C28 (2015) Takahiko Sugihara [Japon] ; Tatsuro Ishizaki [Japon] ; Tadashi Hosoya [Japon] ; Shoko Iga [Japon] ; Waka Yokoyama [Japon] ; Fumio Hirano [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon]Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
000D92 (2015) Ryoko Sakai [Japon] ; Soo-Kyung Cho [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Michi Tanaka [Japon] ; Ryuji Koike [Japon] ; Yoshiya Tanaka [Japon] ; Kazuyoshi Saito [Japon] ; Shintaro Hirata [Japon] ; Koichi Amano [Japon] ; Hayato Nagasawa [Japon] ; Takayuki Sumida [Japon] ; Taichi Hayashi [Japon] ; Takahiko Sugihara [Japon] ; Hiroaki Dobashi [Japon] ; Shinsuke Yasuda [Japon] ; Tetsuji Sawada [Japon] ; Kazuhiko Ezawa [Japon] ; Atsuhisa Ueda [Japon] ; Takao Fujii [Japon] ; Kiyoshi Migita [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon]Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
000E01 (2015) Minoru Fujimoto [Japon] ; Satoshi Serada [Japon] ; Katsuya Suzuki [Japon] ; Ayumi Nishikawa [Japon] ; Atsushi Ogata [Japon] ; Toshihiro Nanki [Japon] ; Kunihiro Hattori [Japon] ; Hitoshi Kohsaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Tsutomu Takeuchi [Japon] ; Tetsuji Naka [Japon]Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
000F02 (2015) Tadashi Hosoya [Japon] ; Fumitaka Mizoguchi ; Hisanori Hasegawa ; Keiko Miura ; Ryuji Koike ; Tetsuo Kubota ; Nobuyuki Miyasaka ; Hitoshi KohsakaA Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A Mutations Successfully Treated with Tocilizumab.
001031 (2016) Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
001074 (2016) Masayoshi Harigai ; Toshihiro Nanki ; Ryuji Koike ; Michi Tanaka ; Kaori Watanabe-Imai ; Yukiko Komano ; Ryoko Sakai ; Hayato Yamazaki ; Takao Koike [Japon] ; Nobuyuki Miyasaka [Japon]Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.
001A81 (2018) Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
001F59 (2019) Masaru Kato [Japon] ; Yuko Kaneko [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Isao Yokota [Japon] ; Tatsuya Atsumi [Japon] ; Tsutomu Takeuchi [Japon]Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i -k "Nobuyuki Miyasaka" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Author.i  \
                -Sk "Nobuyuki Miyasaka" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Nobuyuki Miyasaka
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021